表紙
市場調查報告書
商品編碼
974917

單細胞測序服務/技術市場(2020-2030)

Single-cell Sequencing Services and Technologies Market, 2020-2030

出版日期: | 出版商: Roots Analysis | 英文 220 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告分析了單細胞測序服務和技術的全球市場,包括市場的基本結構,最新發展(主要產品/公司)以及整體市場趨勢展望(2020年∼2025年),專利獲取趨勢,投資和資金/採購動向,各種服務/技術提供商的趨勢,主要公司的概況,當前問題和未來市場機會等。

目錄

第1章簡介

第2章執行摘要

第3章簡介

  • 分析摘要
  • 單細胞測序概述
    • 批量RNA和單細胞RNA序列的比較
  • 用於單細胞測序
    • 癌症研究
    • 臨床診斷
    • 藥物發現
    • 發展科學
    • 免疫學
    • 微生物學
    • 神經病學
    • 器官發育
  • 與單細胞測序有關的問題
    • 數據預處理
    • 捕獲效率低
    • 嚴格而不確定的統計框架
    • 缺乏適當的質量控制體系
  • 未來展望

第4章市場情況:單細胞測序服務提供商

  • 分析摘要
  • 單細胞測序服務提供商:商業企業的市場狀況
    • 成立年份分析
    • 按公司規模分析
    • 總公司所在地分析
    • 使用的測序方法進行分析
    • 按提供的服務類型進行分析
    • 按使用的圖書館準備系統的類型進行分析
    • 按使用的序列系統類型進行分析
  • 單細胞測序服務提供商:非營利組織的市場狀況
    • 按組織位置分析
    • 使用的測序方法進行分析
    • 按提供的服務類型進行分析
    • 按所用圖書館準備系統的類型進行分析
    • 按使用的序列系統類型進行分析

第5章市場情況:單細胞測序技術提供商

  • 分析摘要
  • 單細胞測序系統/技術:工作流程設備的市場狀況
    • 靶核酸分析
    • 按應用程序類型分析
    • 按吞吐量分析
  • 單細胞測序系統和技術:公司發展狀況
    • 成立年份分析
    • 按公司規模分析
    • 總公司所在地分析
  • 單細胞測序系統和技術:測序設備的市場狀況
    • 按應用程序類型分析
    • 通過最大輸出進行分析
    • 通過最大讀取長度進行分析
    • 通過系統效率進行分析
    • 按化學物質進行分析以進行測序
  • 單細胞測序系統和技術:開發人員情況
    • 成立年份分析
    • 按公司規模分析
    • 總公司所在地分析

第6章單細胞測序技術:競爭力分析

  • 分析摘要
  • 主要參數和分析方法
  • 競爭力分析:單細胞工作流程設備
  • 競爭力分析:單細胞測序設備

第7章公司簡介:單細胞測序服務提供商

  • 分析摘要
  • 主動圖案
    • 公司簡介
    • 最新趨勢和未來前景
  • Admera Health
  • Annoroad Genomics
  • BGI Genomics
  • CD Genomics
  • MedGenome
  • Quick Biology
  • SingulOmics

第8章公司簡介:單細胞測序技術提供商

  • 10倍基因組學
    • 公司簡介
    • 財務信息
    • 產品組合
    • 最新趨勢和未來前景
  • Cell Microsystems
  • Fluidigm
  • Illumina
  • Mission Bio
  • Oxford Nanopore Technologies

第9章專利分析

  • 分析摘要
  • 分析範圍/方法
  • 單細胞測序:專利分析
    • 按出版年份分析
    • 區域分析
    • CPC(通用專利分類)組分析
    • 詞云:新的優先領域
    • 按申請人類型分析
    • 主要公司:按專利數量分析
  • 單細胞測序:對比分析
    • 按趨勢分析專利趨勢
    • 區域分析
  • 單細胞測序:專利評估分析

第10章研究補助金分析

  • 分析摘要
  • 分析範圍/方法
  • 單細胞測序:研究經費分析
    • 年度分析
    • 按補助金金額分析
    • 按優先級分析字段
    • 按活動分類代碼分析
    • 按支持期限分析
    • 按融資機制分析
    • 撥款提供者/中心的分析
    • 按接收組織類型分析
    • 受歡迎的接受組織:按贈款金額分析
    • 傑出的計劃官員:按金額分析贈款

第11章最新發展:單細胞測序市場

  • 分析摘要
  • 單細胞測序:最近的業務聯盟(夥伴關係)
    • 商業聯盟模型
    • 按年齡分析業務聯盟
    • 按合同類型分析
    • 按優先領域分析業務聯盟
    • 商業聯盟數量:按地區分析
  • 單細胞測序:最近的資金和投資趨勢
    • 資金:年度分析
    • 資金:按類型分析
    • 按投資額分析
    • 最活躍的公司:按投資額分析
    • 最活躍的投資者:按投資數量分析
  • 單細胞測序:最近推出的產品
    • 按產品發佈年份分析
    • 按產品類型分析
    • 按優先級分析字段
    • 最活躍的公司:按產品發佈數量進行分析

第12章市場規模和機會分析

  • 分析摘要
  • 分析範圍/方法
  • 單細胞測序服務/技術:總體市場機會
  • 單細胞測序服務/技術市場機會:按主要領域劃分(2020-2030)
  • 單細胞測序服務/技術市場機會:
  • 單細胞測序服務/技術市場機會:按最終用戶劃分(2020/2030)
  • 單細胞測序服務/技術市場機會:按應用領域(2020/2030)
  • 單細胞測序服務/技術市場機會:按地區劃分(2020/2030)
    • 北美
    • 歐洲
    • 亞太地區
    • 其他國家(RoW)

第13章結論

第14章企業管理的考慮/意見

  • 分析摘要
  • Genuity Science
    • 公司簡介
    • 採訪概要

第15章附錄I:匯總數據

目錄

Overview:

Over the years, technological advances in the field of genomics have enabled pharma companies to adopt a more personalized and targeted approach to drug / therapy development. Specifically, next-generation sequencing (NGS) technologies have enabled millions of human genomes across diverse ethnicities, to be sequenced. The large volumes of genomic data from the aforementioned sequencing studies have led to the generation of valuable insights on individuals' likely responses to different treatment regimens. Innovation in this field have made NGS technologies increasingly affordable and accessible. In fact, the cost of sequencing a single genome has dropped from USD ~3 billion (Human Genome Project 1990) to USD 1,000 (Illumina sequencing kits) over the last two decades. However, NGS based analyses are limited to offering averaged insights on gene expression. In other words, this method is incapable of quantifying nucleic acid content in individual cells, and thereby, offering gene expression information at single cell resolution. To better understand the interactions of individual cells with their microenvironment, advanced molecular probing solutions are required. In this context, high-throughput single-cell analysis, an emerging analytical technique, is considered a powerful means for studying individual cells, enabling researchers to study gene expression at single cell resolution.

Single-cell sequencing techniques offer many advantages over traditional genomic analyses, enabling the detection of complex and rare cell populations, and elucidating development trajectories of distinct cell lineages. Despite the potential to be used across diverse segments in biotechnology and medical research, this technique is still limited to early-stage research activities. This is primarily attributed to certain challenges associated with data processing and quality control. Further, the lack of versatile in silico tools is also considered among the major roadblocks to meaningful analysis and interpretation of single cell sequencing data. Additionally, the high cost of process execution and affiliated labor intensive protocols are other barriers to the adoption of since-cell sequencing technology. However, the introduction of the RNA-QC-Chain tool in 2018 (an effort to address the data processing and quality control related challenges) and the Human Cell Atlas project (responsible for developing the first whole transcriptome map of human cells) , are considered prominent milestones in the field of single cell genomics. Presently, experts believe that the single-cell genomics market in North America, may reach USD 5 billion by 2025. Given, the potential of single-cell RNA sequencing (scRNA-seq) technologies to probe into previously unelucidated cellular mechanisms, and identify novel biomarkers / therapeutic targets, they are likely to witness significant adoption in biomedical research over the next decade.

Scope of the Report:

The 'Single-cell Sequencing Services and Technologies Market, 2020-2030' report features an extensive study of the current landscape and the future opportunities associated with single-cell sequencing services / technologies.

In addition to other elements, the report features:

  • An overview of the competitive landscape of single-cell sequencing service providers providing information on a number of parameters, such as year of establishment, company size, geographical location, sequencing method used (DNA sequencing, RNA sequencing, ATAC sequencing and DNA methylation), types of services offered (library preparation, sequencing and bioinformatics), type of library preparation system used and type of sequencing system used.
  • A detailed review of the competitive market landscape of single-cell sequencing workflow instruments providing information on a number of relevant parameters, such as target nucleic acid (DNA, RNA and protein), type of application (cell isolation, cDNA amplification and library preparation) and throughput. In addition, the report features competitive market landscape of single-cell sequencing systems providing information on parameters, such as type of application (single-cell, whole genome, whole exome and targeted sequencing), maximum output, maximum read length, system efficiency, sequencing chemistry (sequencing-by-synthesis, SMRT sequencing and nanopore sequencing). It also includes an analysis on the companies developing these systems, based on year of establishment, company size and geographical location.
  • An insightful competitiveness analysis of single-cell sequencing technologies based on relevant parameters, such as supplier power (based on a company's employee count and years of experience) and other important technology related specifications, such as maximum sequencing output, maximum reads per run, maximum read length, quality score, applications and cost of sequencer.
  • Elaborate profiles of companies that are engaged in offering single-cell sequencing services and technologies. Each profile features a brief overview of the company, its financial information (if available), proprietary technology platform(s), recent developments and an informed future outlook.
  • An in-depth analysis of the various patents that have been filed / granted for single-cell sequencing technologies, based on parameters, such as patent type, publication year, geographical location, Cooperative Patent Classification (CPC) symbols, emerging focus areas, and type of applicant, highlighting the leading industry / non-industry players (in terms of the size of intellectual property portfolio) . It also features a patent benchmarking and valuation analysis.
  • A detailed analysis of the grants that have been awarded to research institutes engaged in projects related to single-cell sequencing, between 2016 and 2020, based on multiple parameters, such as year of grant award, grant amount, focus area, activity code, support period, funding mechanism, funding institute center, type of recipient organization, popular recipient organizations and prominent program officers.
  • An analysis of various developments / recent trends related to single-cell sequencing, offering insights on [A] partnerships and collaborations established within the industry, [B] funding and investments, and [C] recent product launches related to single-cell sequencing.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity within the market. Based on several parameters, such as number of single-cell samples sequenced annually, average cost of sequencing, and growth trends across various geographies, we have provided an informed estimate of the likely evolution of the market, in the mid to long term, for the period 2020-2030. The chapter features the likely distribution of the opportunity across different [A] key market segments (services and technologies), [B] type of system (sequencing and workflow instruments), [C] end-user (pharmaceutical companies, academic and research institutions and other end-users), [D] area of application (diagnostics, drug discovery, precision medicine and others) and [E] geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain.

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the leading single-cell sequencing service and technology providers?
  • What are the recent developments in the single-cell sequencing domain?
  • Which organizations have filed the maximum number of patents in this field?
  • Which institutions have received the maximum grant funding?
  • What factors are likely to influence the evolution of this upcoming market?
  • How is the current and future opportunity likely to be distributed across key market segments?

Chapter Outlines:

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the single-cell sequencing market in the mid to long term.

Chapter 3 provides an overview of single-cell sequencing, and the process involved in single-cell sequencing and analysis. It also highlights different applications of single-cell sequencing in life sciences, specifically in cancer research, clinical diagnostics, drug discovery, embryology, immunology, microbiology, neurology and organ development. Further, the chapter highlights the key challenges associated with the adoption of single-cell sequencing and its future perspectives.

Chapter 4 provides an overview of the competitive landscape of single-cell sequencing service providers, including a detailed analysis based on parameters, such as year of establishment, company size, geographical location, sequencing method used (DNA sequencing, RNA sequencing, ATAC sequencing and DNA methylation), types of service offered (library preparation, sequencing and bioinformatics), types of library preparation system used and types of sequencing system used.

Chapter 5 provides an overview of the market landscape of single-cell sequencing workflow instruments, including an analysis based on parameters, such as type of target nucleic acid (DNA, RNA and protein), type of application (cell isolation, cDNA amplification and library preparation) and throughput. In addition, the report features study of market landscape of single-cell sequencing systems providing information on parameters, such as type of application (single-cell, whole genome, whole exome and targeted sequencing), maximum output, maximum read length, system efficiency, sequencing chemistry (sequencing-by-synthesis, SMRT sequencing and nanopore sequencing), year of establishment, company size and geographical location. It also includes an analysis on the companies developing these systems, based on year of establishment, company size and geographical location.

Chapter 6 provides a detailed competitiveness analysis of single-cell sequencing technologies based on several relevant parameters, such as supplier power (based on company's employee count and years of experience) and product related specifications (type of sequencing, type of services offered, throughput)

Chapter 7 includes detailed profiles of the companies offering single-cell sequencing services, featuring a brief overview of the company, recent developments and an informed future outlook.

Chapter 8 includes detailed profiles of the companies offering single-cell sequencing platforms and technologies, featuring a brief overview of the company, its financial information (if available), proprietary platform(s), recent developments and an informed future outlook.

Chapter 9 presents an in-depth analysis of the various patents that have been filed / granted related to single-cell sequencing, based on key parameters, such as patent type, publication year, geographical location, CPC symbol, emerging focus areas, and type of applicant, highlighting the leading industry / non-industry players (in terms of the size of intellectual property portfolio). It also features a patent benchmarking and valuation analysis.

Chapter 10 provides a detailed study of the various grants that have been awarded to research institutes engaged in projects related to single-cell sequencing, between 2016 and 2020, including an analysis based on multiple parameters, such as year of grant award, grant amount, focus area, activity code, support period, funding mechanism, funding institute center, type of recipient organization, popular recipient organizations and prominent program officers.

Chapter 11 provides an analysis of various developments / recent trends related to single-cell sequencing, offering insights on [A] partnerships and collaborations established within the industry, [B] funding and investments, and [C] recent product launches related to single-cell sequencing.

Chapter 12 presents a detailed market forecast, highlighting the future potential of the single-cell sequencing services and technologies market till the year 2030. The chapter features the likely distribution of the opportunity across different [A] key market segments (services and technologies), [B] type of system (sequencing and workflow instruments), [C] end-user (pharmaceutical companies, academic and research institutions and other end-users), [D] area of application (diagnostics, drug discovery, precision medicine and others) and [E]geographical regions (North America, Europe, Asia-Pacific and rest of the world).

Chapter 13 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it summarizes the various evolutionary trends that are likely to influence the future of this market.

Chapter 14 is a collection of executive insight(s) of the discussion(s) that were held with key stakeholder(s) in this market.

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research and Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of Single-Cell Sequencing
    • 3.2.1. Comparison of Bulk RNA and Single-cell RNA Sequencing
  • 3.3. Applications of Single-cell Sequencing
    • 3.3.1. In Cancer Research
    • 3.3.2. In Clinical Diagnostics
    • 3.3.3. In Drug Discovery
    • 3.3.4. In Embryology
    • 3.3.5. In Immunology
    • 3.3.6. In Microbiology
    • 3.3.7. In Neurology
    • 3.3.8. In Organ Development
  • 3.4. Challenges Associated with Single-cell Sequencing
    • 3.4.1. Data Pre-processing
    • 3.4.2. Low Capturing Efficiency
    • 3.4.3. Rigid and Undefined Statistical Frameworks
    • 3.4.4. Lack of Appropriate Quality Control Systems
  • 3.5. Future Perspectives

4. MARKET LANDSCAPE: SINGLE-CELL SEQUENCING SERVICE PROVIDERS

  • 4.1. Chapter Overview
  • 4.2. Single-cell Sequencing Service Providers: Market Landscape of Industry Players
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Sequencing Method Used
    • 4.2.5. Analysis by Type of Service Offered
    • 4.2.6. Analysis by Type of Library Preparation System Used
    • 4.2.7. Analysis by Type of Sequencing System Used
  • 4.3. Single-cell Sequencing Service Providers: Market Landscape of Non-Industry Players
    • 4.3.1. Analysis by Location of Organization
    • 4.3.2. Analysis by Sequencing Method Used
    • 4.3.3. Analysis by Type of Service Offered
    • 4.3.4. Analysis by Type of Library Preparation System Used
    • 4.3.5. Analysis by Type of Sequencing System Used

5. MARKET LANDSCAPE: SINGLE-CELL SEQUENCING TECHNOLOGY PROVIDERS

  • 5.1. Chapter Overview
  • 5.2. Single-cell Sequencing Systems and Technologies: Market Landscape of Workflow Instruments
    • 5.2.1. Analysis by Target Nucleic Acid
    • 5.2.2. Analysis by Type of Application
    • 5.2.3. Analysis by Throughput
  • 5.3. Single-cell Sequencing Systems and Technologies: Developer Landscape
    • 5.3.4. Analysis by Year of Establishment
    • 5.3.5. Analysis by Company Size
    • 5.3.6. Analysis by Location of Headquarters
  • 5.4. Single-cell Sequencing Systems and Technologies: Market Landscape of Sequencing Instruments
    • 5.4.1. Analysis by Type of Application
    • 5.4.2. Analysis by Maximum Output
    • 5.4.3. Analysis by Maximum Read Length
    • 5.4.4. Analysis by System Efficiency
    • 5.4.5. Analysis by Sequencing Chemistry
  • 5.5. Single-cell Sequencing Systems and Technologies: Developer Landscape
    • 5.5.6. Analysis by Year of Establishment
    • 5.5.7. Analysis by Company Size
    • 5.5.8. Analysis by Location of Headquarters

6. SINGLE-CELL SEQUENCING TECHNOLOGIES: COMPETITIVENESS ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Key Parameters and Methodology
  • 6.3. Competitiveness Analysis: Single-cell Workflow Instruments
  • 6.4. Competitiveness Analysis: Single-cell Sequencing Instruments

7. COMPANY PROFILES: SINGLE-CELL SEQUENCING SERVICE PROVIDERS

  • 7.1. Chapter Overview
  • 7.2. Active Motif
    • 7.2.1. Company Overview
    • 7.2.2. Recent Developments and Future Outlook
  • 7.3. Admera Health
    • 7.3.1. Company Overview
    • 7.3.2. Recent Developments and Future Outlook
  • 7.4. Annoroad Genomics
    • 7.4.1. Company Overview
    • 7.4.2. Recent Developments and Future Outlook
  • 7.5. BGI Genomics
    • 7.5.1. Company Overview
    • 7.5.2. Recent Developments and Future Outlook
  • 7.6. CD Genomics
    • 7.6.1. Company Overview
    • 7.6.2. Recent Developments and Future Outlook
  • 7.7. MedGenome
    • 7.7.1. Company Overview
    • 7.7.2. Recent Developments and Future Outlook
  • 7.8. Quick Biology
    • 7.8.1. Company Overview
    • 7.8.2. Recent Developments and Future Outlook
  • 7.9. SingulOmics
    • 7.9.1. Company Overview
    • 7.9.2. Recent Developments and Future Outlook

8. COMPANY PROFILES: SINGLE CELL SEQUENCING TECHNOLOGY PROVIDERS

  • 8.1. 10x Genomics
    • 8.1.1. Company Overview
    • 8.1.2. Financial Information
    • 8.1.3. Product Portfolio
      • 8.1.3.1. 10x Chromium
    • 8.1.4. Recent Developments and Future Outlook
  • 8.2. Cell Microsystems
    • 8.2.1. Company Overview
    • 8.2.2. Product Portfolio
      • 8.2.2.1. Cellraft AIR
  • 8.3. Fluidigm
    • 8.3.1. Company Overview
    • 8.3.2. Financial information
    • 8.3.3. Product Portfolio
      • 8.3.3.1. Fluidigm C1
    • 8.3.4. Recent Developments and Future Outlook
  • 8.4. Illumina
    • 8.4.2. Financial Information
    • 8.4.3. Product Portfolio
      • 8.4.3.1. MiSeq Series
      • 8.4.3.2. Nextseq Series
      • 8.4.3.3. NovaSeq 6000 System
    • 8.4.4. Recent Developments and Future Outlook
  • 8.5. Mission Bio
    • 8.5.1. Company Overview
    • 8.5.2. Product Portfolio
      • 8.5.2.1. Tapestri
    • 8.5.3. Recent Developments and Future Outlook
  • 8.6. Oxford Nanopore Technologies
    • 8.6.1. Company Overview
    • 8.6.2. Financial Information
    • 8.6.3. Product Portfolio
      • 8.6.3.1. MinIon Systems
      • 8.6.3.2. PromethIon Systems
    • 8.6.4. Recent Developments and Future Outlook

9. PATENT ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Scope and Methodology
  • 9.3. Single-cell Sequencing: Patent Analysis
    • 9.3.1. Analysis by Publication Year
    • 9.3.2. Analysis by Geographical Location
    • 9.3.3. Analysis by CPC Symbols
    • 9.3.4. Word Cloud: Emerging Focus Areas
    • 9.3.5. Analysis by Type of Applicant
    • 9.3.6. Leading Players: Analysis by Number of Patents
  • 9.4. Single-cell Sequencing: Benchmarking Analysis
    • 9.4.1. Analysis by Patent Characteristics
    • 9.4.2. Analysis by Geography
  • 9.5. Single-cell Sequencing: Patent Valuation Analysis

10. ACADEMIC GRANT ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Single-cell Sequencing: Analysis of Academic Grants
    • 10.3.1. Analysis by Year of Grant Award
    • 10.3.2. Analysis by Grant Amount
    • 10.3.3. Analysis by Focus Area
    • 10.3.4. Analysis by Activity Code
    • 10.3.5. Analysis by Support Period
    • 10.3.6. Analysis by Funding Mechanism
    • 10.3.7. Analysis by Funding Institute Center
    • 10.3.8. Analysis by Type of Recipient Organization
    • 10.3.9. Popular Recipient Organizations: Analysis by Number of Grants
    • 10.3.10. Prominent Program Officers: Analysis by Number of Grants

11. RECENT DEVELOPMENTS: SINGLE-CELL SEQUENCING MARKET

  • 11.1. Chapter Overview
  • 11.2. Single-cell Sequencing: Recent Partnerships
    • 11.2.1. Partnership Models
    • 11.2.2. Analysis by Year of Partnership
    • 11.2.3. Analysis by Type of Agreement
    • 11.2.4. Analysis by Focus Area of Partnership
    • 11.2.5. Regional Analysis by Number of Partnerships
  • 11.3. Single-cell Sequencing: Recent Funding and Investments
    • 11.3.1. Analysis by Year of Funding
    • 11.3.3. Analysis by Type of Funding
    • 11.3.2. Analysis by Amount Invested
    • 11.3.4. Most Active Players: Analysis by Amount Invested
    • 11.3.5. Most Active Investors: Analysis by Number of Funding Instances
  • 11.4. Single-cell Sequencing: Recent Product Launches
    • 11.4.1. Analysis by Year of Product Launch
    • 11.4.2. Analysis by Type of Product
    • 11.4.3. Analysis by Focus Area
    • 11.4.4. Most Active Players: Analysis by Number of Launches

12. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Key Assumptions and Forecast Methodology
  • 12.3. Overall Single-cell Sequencing Services and Technologies Market Opportunity,
  • 12.4. Single-cell Sequencing Services and Technologies Market Opportunity Across Key Market Segments, 2020-2030
  • 12.5. Single-cell Sequencing Services and Technologies Market Opportunity:
  • 12.6. Single-cell Sequencing Services and Technologies Market Opportunity: Distribution by End-User 2020 and 2030
  • 12.7. Single-cell Sequencing Services and Technologies Market Opportunity: Distribution by Area of Application, 2020 and 2030
  • 12.8. Single-cell Sequencing Services and Technologies Market Opportunity: Geographical Distribution, 2020 and 2030
    • 12.8.1. Single-cell Sequencing Services and Technologies Market Opportunity in North America, 2020-2030
      • 12.8.1.1. Single-cell Sequencing Services and Technologies Market Opportunity in North America Across Key Market Segments, 2020-2030
      • 12.8.1.1.1. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Service Providers, 2020-2030
      • 12.8.1.1.2. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Technology Providers, 2020-2030
      • 12.8.1.2. Single-cell Sequencing Services and Technologies Market Opportunity in North America: Distribution by End-Users, 2020-2030
      • 12.8.1.2.1. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Academic and Research Institutions, 2020-2030
      • 12.8.1.2.2. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Pharmaceutical Companies, 2020-2030
      • 12.8.1.2.3. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Other End-Users, 2020-2030
      • 12.8.1.3. Single-cell Sequencing Services and Technologies Market Opportunity in North America: Distribution by Area of Application, 2020-2030
      • 12.8.1.3.1. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Diagnostics, 2020-2030
      • 12.8.1.3.2. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Drug Discovery, 2020-2030
      • 12.8.1.3.3. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Precision Medicine, 2020-2030
      • 12.8.1.3.4. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Other Applications, 2020-2030
    • 12.8.2. Single-cell Sequencing Services and Technologies Market Opportunity in Europe, 2020-2030
      • 12.8.2.1. Single-cell Sequencing Services and Technologies Market Opportunity in Europe Across Key Market Segments, 2020-2030
        • 12.8.2.1.1. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Service Providers, 2020-2030
        • 12.8.2.1.2. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Technology Providers, 2020-2030
      • 12.8.2.2. Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Distribution by End-Users, 2020-2030
        • 12.8.2.2.1. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Academic and Research Institutions, 2020-2030
        • 12.8.2.2.2. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Pharmaceutical Companies, 2020-2030
        • 12.8.2.2.3. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Other End-Users, 2020-2030
      • 12.8.2.3. Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Distribution by Area of Application, 2020-2030
        • 12.8.2.3.1. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Diagnostics, 2020-2030
        • 12.8.2.3.2. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Drug Discovery, 2020-2030
        • 12.8.2.3.3. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Precision Medicine, 2020-2030
      • 12.8.2.3.4. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Other Applications, 2020-2030
    • 12.8.3. Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific, 2020-2030
      • 12.8.3.1. Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific Across Key Market Segments, 2020-2030
        • 12.8.3.1.1. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Service Providers, 2020-2030
        • 12.8.3.1.2. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Technology Providers, 2020-2030
      • 12.8.3.2. Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Distribution by End-Users, 2020-2030
        • 12.8.3.2.1. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Academic and Research Institutions, 2020-2030
        • 12.8.3.2.2. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Pharmaceutical Companies, 2020-2030
        • 12.8.3.2.3. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Other End-Users, 2020-2030
      • 12.8.3.3. Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Distribution by Area of Application, 2020-2030
        • 12.8.3.3.1. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Diagnostics, 2020-2030
        • 12.8.3.3.2. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Drug Discovery, 2020-2030
        • 12.8.3.3.3. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Precision Medicine, 2020-2030
        • 12.8.3.3.4. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Other Applications, 2020-2030
    • 12.8.4. Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World, 2020-2030
      • 12.8.4.1. Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World Across Key Market Segments, 2020-2030
        • 12.8.4.1.1. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Service Providers, 2020-2030
        • 12.8.4.1.2. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Technology Providers, 2020-2030
      • 12.8.4.2. Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Distribution by End-Users, 2020-2030
        • 12.8.4.2.1. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Academic and Research Institutions, 2020-2030
        • 12.8.4.2.2. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Pharmaceutical Companies, 2020-2030
        • 12.8.4.2.3. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Other End-Users, 2020-2030
      • 12.8.4.3. Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Distribution by Area of Application, 2020-2030
        • 12.8.4.3.1. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Diagnostics, 2020-2030
        • 12.8.4.3.2. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Drug Discovery, 2020-2030
        • 12.8.4.3.3. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Precision Medicine, 2020-2030
        • 12.8.4.3.4. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Other Applications, 2020-2030

13. CONCLUSION

  • 13.1. Chapter Overview
  • 13.2. Key Takeaways

14. EXECUTIVE INSIGHTS

  • 14.1. Chapter Overview
  • 14.2. Genuity Science
    • 14.2.1. Company Snapshot
    • 14.2.2. Interview Transcript, Irene Blat, Senior Director of Data Products and Analytics

15. APPENDIX I: TABULATED DATA

List Of Figures

  • Figure 3.1 Process of Single-cell Sequencing
  • Figure 3.2 Bulk RNA Sequencing versus scRNA Sequencing
  • Figure 3.3 Applications of Single-cell Sequencing
  • Figure 3.4 Challenges Associated with Single-cell Sequencing
  • Figure 4.1 Single-cell Sequencing Service Providers (Industry Players): Distribution by Year of Establishment
  • Figure 4.2 Single-cell Sequencing Service Providers (Industry Players): Distribution by Company Size
  • Figure 4.3 Single-cell Sequencing Service Providers (Industry Players): Distribution by Location of Headquarters
  • Figure 4.4 Single-cell Sequencing Service Providers (Industry Players): Distribution by Sequencing Method Used
  • Figure 4.5 Single-cell Sequencing Service Providers (Industry Players): Distribution by Type of Service Offered
  • Figure 4.6 Single-cell Sequencing Service Providers (Industry Players): Distribution by Type of Library Preparation System Used
  • Figure 4.7 Single-cell Sequencing Service Providers (Industry Players): Distribution by Type of Sequencing System Used
  • Figure 4.8 Single-cell Sequencing Service Providers (Non-Industry Players): Distribution by Location of Organization
  • Figure 4.9 Single-cell Sequencing Service Providers (Non-Industry Players): Distribution by Sequencing Method Used
  • Figure 4.10 Single-cell Sequencing Service Providers (Non-Industry Players): Distribution by Type of Service Offered
  • Figure 4.11 Single-cell Sequencing Service Providers (Non-Industry Players): Distribution by Type of Library Preparation System Used
  • Figure 4.12 Single-cell Sequencing Service Providers (Non-Industry Players): Distribution by Type of Sequencing System Used
  • Figure 5.1 Single-cell Sequencing Workflow Instruments: Distribution by Targeted Nucleic Acid
  • Figure 5.2 Single-cell Sequencing Workflow Instruments: Distribution by Type of Application
  • Figure 5.3 Single-cell Sequencing Workflow Instruments: Distribution by Throughput
  • Figure 5.4 Single-cell Sequencing Workflow Instrument Providers: Distribution by Year of Establishment
  • Figure 5.5 Single-cell Sequencing Workflow Instrument Providers: Distribution by Company Size
  • Figure 5.6 Single-cell Sequencing Workflow Instrument Providers: Distribution by Location of Headquarters
  • Figure 5.7 Single-cell Sequencing Instruments: Distribution by Type of Application
  • Figure 5.8 Single-cell Sequencing Instruments: Distribution by Maximum Output
  • Figure 5.9 Single-cell Sequencing Instruments: Distribution by Maximum Read Length
  • Figure 5.10 Single-cell Sequencing Instruments: Distribution by System Efficiency
  • Figure 5.11 Single-cell Sequencing Instruments: Distribution by Sequencing Chemistry
  • Figure 5.12 Single-cell Sequencing Instrument Providers: Distribution by Year of Establishment
  • Figure 5.13 Single-cell Sequencing Instrument Providers: Distribution by Company Size
  • Figure 5.14 Single-cell Sequencing Instrument Providers: Distribution by Location of Headquarters
  • Figure 6.1 Platform Competitiveness Analysis: Single-cell Workflow Instruments (Peer Group I)
  • Figure 6.2 Platform Competitiveness Analysis: Single-cell Workflow Instruments (Peer Group II)
  • Figure 6.3 Platform Competitiveness Analysis: Single-cell Sequencing Instruments (Peer Group I)
  • Figure 6.4 Platform Competitiveness Analysis: Single-cell Sequencing Instruments (Peer Group II)
  • Figure 8.1 10x Genomics: Annual Revenues, 2017-Q2 2020 (USD Million)
  • Figure 8.2 Fluidigm: Annual Revenues, 2015-Q2 2020 (USD Million)
  • Figure 8.3 Illumina: Annual Revenues, 2013-Q2 2020 (USD Billion)
  • Figure 8.4 Illumina: Sequencing Systems Portfolio
  • Figure 8.5 Oxford Nanopore Technologies: Sequencing Systems Portfolio
  • Figure 9.1 Patent Analysis: Distribution by Patent Type
  • Figure 9.2 Patent Analysis: Cumulative Distribution by Publication Year, 2015-2020
  • Figure 9.3 Patent Analysis: Distribution by Geographical Location and Publication Year (Pre 2015- 2020)
  • Figure 9.4 Patent Analysis: Distribution by Patent Type and Publication Year
  • Figure 9.5 Patent Analysis: Distribution by Geographical Location
  • Figure 9.6 Patent Analysis: Distribution by Jurisdiction
  • Figure 9.7 Patent Analysis: Distribution by CPC Symbols
  • Figure 9.8 Patent Analysis: Emerging Focus Areas
  • Figure 9.9 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant (Pre 2015-2019)
  • Figure 9.10 Leading Players: Distribution by Number of Patents
  • Figure 9.11 Patent Analysis (Leading Players): Benchmarking by Patent Characteristics (CPC Classifications)
  • Figure 9.12 Patent Analysis: Benchmarking by International Patents
  • Figure 9.13 Patent Analysis: Distribution of Patents by Geographical Region and Patent Type
  • Figure 9.14 Single-cell Sequencing: Age of Patents
  • Figure 9.15 Patent Analysis: Valuation Analysis
  • Figure 10.1 Academic Grant Analysis: Cumulative Year-wise Trend, 2016-2020
  • Figure 10.2 Academic Grant Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
  • Figure 10.3 Academic Grant Analysis: Distribution by Focus Area
  • Figure 10.4 Academic Grant Analysis: Distribution by Activity Code
  • Figure 10.5 Academic Grant Analysis: Distribution by Support Period
  • Figure 10.6 Academic Grant Analysis: Distribution by Funding Mechanism
  • Figure 10.7 Academic Grant Analysis: Distribution of Funding Institute Center by Support Year and Number of Grants
  • Figure 10.8 Academic Grant Analysis: Distribution by Type of Recipient Organization
  • Figure 10.9 Popular Recipient Organizations: Distribution across States in the US
  • Figure 10.10 Popular Recipient Organizations: Distribution by Number of Grants
  • Figure 10.11 Popular Recipient Organizations: Distribution by Amount Awarded (USD Million)
  • Figure 10.12 Prominent Program Officers: Distribution by Number of Grants
  • Figure 11.1 Recent Partnerships: Distribution by Year of Partnership
  • Figure 11.2 Recent Partnerships: Distribution by Type of Agreement
  • Figure 11.3 Recent Partnerships: Distribution by Focus Area of Partnership
  • Figure 11.4 Recent Partnerships: Regional Distribution
  • Figure 11.5 Recent Investments: Distribution by Year of Funding
  • Figure 11.6 Recent Investments: Distribution by Type of Funding
  • Figure 11.7 Recent Investments: Distribution by Amount Invested (USD Million)
  • Figure 11.8 Most Active Players: Distribution by Amount Invested
  • Figure 11.9 Most Active Investors: Distribution by Number of Funding Instances
  • Figure 11.10 Recent Product Launches: Distribution by Year of Product Launch
  • Figure 11.11 Recent Product Launches: Distribution by Type of Product
  • Figure 11.12 Recent Product Launches: Distribution by Focus Area
  • Figure 11.13 Most Active Players: Distribution by Number of Product Launches
  • Figure 12.1 Overall Single-cell Sequencing Services and Technologies Market Opportunity, 2020-2030 (USD Million)
  • Figure 12.2 Single-cell Sequencing Services and Technologies Market Opportunity Across Key Market Segments, 2020 and 2030 (USD Million)
  • Figure 12.3 Single-cell Sequencing Services and Technologies Market Opportunity: Distribution by Type of System, 2020 and 2030 (USD Million)
  • Figure 12.4 Single-cell Sequencing Services and Technologies Market Opportunity: Distribution by End-User, 2020 and 2030 (USD Million)
  • Figure 12.5 Single-cell Sequencing Services and Technologies Market Opportunity: Distribution by Area of Application, 2020 and 2030 (USD Million)
  • Figure 12.6 Single-cell Sequencing Services and Technologies Market Opportunity: Geographical Distribution, 2020 and 2030 (USD Million)
  • Figure 12.7 Single-cell Sequencing Services and Technologies Market Opportunity in North America, 2020-2030 (USD Million)
  • Figure 12.8 Single-cell Sequencing Services and Technologies Market Opportunity in North America: Share of Service Providers, 2020-2030 (USD Million)
  • Figure 12.9 Single-cell Sequencing Services and Technologies Market Opportunity in North America: Share of Technology Providers, 2020-2030 (USD Million)
  • Figure 12.10 Single-cell Sequencing Services and Technologies Market Opportunity in North America: Share of Academic and Research Institutions, 2020-2030 (USD Million)
  • Figure 12.11 Single-cell Sequencing Services and Technologies Market Opportunity in North America: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
  • Figure 12.12 Single-cell Sequencing Services and Technologies Market Opportunity in North America: Share of Other End-Users, 2020-2030 (USD Million)
  • Figure 12.13 Single-cell Sequencing Services and Technologies Market Opportunity in North America: Share of Diagnostics, 2020-2030 (USD Million)
  • Figure 12.14 Single-cell Sequencing Services and Technologies Market Opportunity in North America: Share of Drug Discovery, 2020-2030 (USD Million)
  • Figure 12.15 Single-cell Sequencing Services and Technologies Market Opportunity in North America: Share of Precision Medicine, 2020-2030 (USD Million)
  • Figure 12.16 Single-cell Sequencing Services and Technologies Market Opportunity in North America: Share of Other Applications, 2020-2030 (USD Million)
  • Figure 12.17 Single-cell Sequencing Services and Technologies Market Opportunity in Europe, 2020-2030 (USD Million)
  • Figure 12.18 Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Service Providers, 2020-2030 (USD Million)
  • Figure 12.19 Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Technology Providers, 2020-2030 (USD Million)
  • Figure 12.20 Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Academic and Research Institutions, 2020-2030 (USD Million)
  • Figure 12.21 Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
  • Figure 12.22 Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Other End-Users, 2020-2030 (USD Million)
  • Figure 12.23 Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Diagnostics, 2020-2030 (USD Million)
  • Figure 12.24 Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Drug Discovery, 2020-2030 (USD Million)
  • Figure 12.25 Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Precision Medicine, 2020-2030 (USD Million)
  • Figure 12.26 Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Other Applications, 2020-2030 (USD Million)
  • Figure 12.27 Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific, 2020-2030 (USD Million)
  • Figure 12.28 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Service Providers, 2020-2030 (USD Million)
  • Figure 12.29 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Technology Providers, 2020-2030 (USD Million)
  • Figure 12.30 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Academic and Research Institutions, 2020-2030 (USD Million)
  • Figure 12.31 Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
  • Figure 12.32 Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Share of Other End-Users, 2020-2030 (USD Million)
  • Figure 12.33 Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Share of Diagnostics, 2020-2030 (USD Million)
  • Figure 12.34 Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Share of Drug Discovery, 2020-2030 (USD Million)
  • Figure 12.35 Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Share of Precision Medicine, 2020-2030 (USD Million)
  • Figure 12.36 Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Share of Other Applications, 2020-2030 (USD Million)
  • Figure 12.37 Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World, 2020-2030 (USD Million)
  • Figure 12.38 Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Service Providers, 2020-2030 (USD Million)
  • Figure 12.39 Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Technology Providers, 2020-2030 (USD Million)
  • Figure 12.40 Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Academic and Research Institutions, 2020-2030 (USD Million)
  • Figure 12.41 Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
  • Figure 12.42 Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Other End-Users, 2020-2030 (USD Million)
  • Figure 12.43 Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Diagnostics, 2020-2030 (USD Million)
  • Figure 12.44 Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Drug Discovery, 2020-2030 (USD Million)
  • Figure 12.45 Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Precision Medicine, 2020-2030 (USD Million)
  • Figure 12.46 Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Other Applications, 2020-2030 (USD Million)

List Of Tables

  • Table 3.1 Comparison of Bulk RNA Sequencing and scRNA Sequencing
  • Table 4.1 Single-cell Sequencing Service Providers: List of Industry Players
  • Table 4.2 Single-cell Sequencing Service Providers (Industry Players): Information on Sequencing Method, Turn Around Time and Sample Used
  • Table 4.3 Single-cell Sequencing Service Providers (Industry Players): Information on Type of Service Offered, Library Preparation System Used and Sequencing System Used
  • Table 4.4 Single-cell Sequencing Providers: List of Non-Industry Players
  • Table 4.5 Single-cell Sequencing Service Providers (Non-Industry Players): Information on Sequencing Method Used, Turn Around Time and Price of Services
  • Table 4.6 Single-cell Sequencing Service Providers (Non-Industry Players): Information on Type of Service Offered, Library Preparation System Used and Sequencing System Used
  • Table 4.7 Additional List of Companies
  • Table 5.1 Single-cell Sequencing Workflow Instruments: Information on Name of Developer, Target Nucleic Acid and System Throughput
  • Table 5.2 Single-cell Sequencing Workflow Instruments: Information on Type of Application and Analytical Software Used
  • Table 5.3 List of Single-cell Sequencing Workflow Instrument Providers
  • Table 5.4 Single-cell Sequencing Instruments: Information on Type of Application, Run Time, Maximum Output and Output Range
  • Table 5.5 Single-cell Sequencing Instruments: Information on Maximum Reads per Run, Reads per Run, Maximum Read Length, Maximum Quality Score, Sequencing Chemistry and Cost of Instrument
  • Table 5.6 List of Single-cell Sequencing Instrument Providers
  • Table 7.1 Single-cell Sequencing Service Providers: List of Profiled Companies
  • Table 7.2 Active Motif: Company Snapshot
  • Table 7.3 Admera Health: Company Snapshot
  • Table 7.4 Admera Health: Recent Developments and Future Outlook
  • Table 7.5 Annoroad Genomics: Company Snapshot
  • Table 7.6 Annoroad Genomics: Recent Developments and Future Outlook
  • Table 7.7 BGI Genomics: Company Snapshot
  • Table 7.8 BGI Genomics: Recent Developments and Future Outlook
  • Table 7.9 CD Genomics: Company Snapshot
  • Table 7.10 CD Genomics: Recent Developments and Future Outlook
  • Table 7.11 MedGenome: Company Snapshot
  • Table 7.12 MedGenome: Recent Developments and Future Outlook
  • Table 7.13 Quick Biology: Company Snapshot
  • Table 7.14 Quick Biology: Recent Developments and Future Outlook
  • Table 7.15 SingulOmics: Company Snapshot
  • Table 8.1 10x Genomics: Company Snapshot
  • Table 8.2 10x Genomics: Recent Developments and Future Outlook
  • Table 8.3 Cell Microsystems: Company Snapshot
  • Table 8.4 Fluidigm: Company Snapshot
  • Table 8.5 Fluidigm: Recent Developments and Future Outlook
  • Table 8.6 Illumina: Company Snapshot
  • Table 8.7 Illumina: Recent Developments and Future Outlook
  • Table 8.8 Mission Bio: Company Snapshot
  • Table 8.9 Mission Bio: Recent Developments and Future Outlook
  • Table 8.10 Oxford Nanopore Technologies: Company Snapshot
  • Table 8.11 Oxford Nanopore Technologies: Recent Developments and Future Outlook
  • Table 9.1 Patent Analysis: CPC Symbols
  • Table 9.2 Patent Analysis: Most Popular CPC Symbols
  • Table 9.3 Patent Analysis: List of Top 10 CPC Symbols
  • Table 9.4 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 9.5 Patent Analysis: List of Relatively Higher Value Patents
  • Table 15.1 Single-cell Sequencing Service Providers (Industry Players): Distribution by Year of Establishment
  • Table 15.2 Single-cell Sequencing Service Providers (Industry Players): Distribution by Company Size
  • Table 15.3 Single-cell Sequencing Service Providers (Industry Players): Distribution by Location of Headquarters
  • Table 15.4 Single-cell Sequencing Service Providers (Industry Players): Distribution by Sequencing Method Used
  • Table 15.5 Single-cell Sequencing Service Providers (Industry Players): Distribution by Type of Service Offered
  • Table 15.6 Single-cell Sequencing Service Providers (Industry Players): Distribution by Type of Library Preparation System Used
  • Table 15.7 Single-cell Sequencing Service Providers (Industry Players): Distribution by Type of Sequencing System Used
  • Table 15.8 Single-cell Sequencing Service Providers (Non-Industry Players): Distribution by Location of Organization
  • Table 15.9 Single-cell Sequencing Service Providers (Non-Industry Players): Distribution by Sequencing Method Used
  • Table 15.10 Single-cell Sequencing Service Providers (Non-Industry Players): Distribution by Types of Service Offered
  • Table 15.11 Single-cell Sequencing Service Providers (Non-Industry Players): Distribution by Type of Library Preparation System Used
  • Table 15.12 Single-cell Sequencing Service Providers (Non-Industry Players): Distribution by Type of Sequencing System Used
  • Table 15.13 Single-cell Sequencing Workflow Instruments: Distribution by Target Nucleic Acid
  • Table 15.14 Single-cell Sequencing Workflow Instruments: Distribution by Type of Application
  • Table 15.15 Single-cell Sequencing Workflow Instruments: Distribution by Throughput
  • Table 15.16 Single-cell Sequencing Workflow Instrument Providers: Distribution by Year of Establishment
  • Table 15.17 Single-cell Sequencing Workflow Instrument Providers: Distribution by Company Size
  • Table 15.18 Single-cell Sequencing Workflow Instrument Providers: Distribution by Location of Headquarters
  • Table 15.19 Single-cell Sequencing Instruments: Distribution by Type of Application
  • Table 15.20 Single-cell Sequencing Instruments: Distribution by Maximum Output
  • Table 15.21 Single-cell Sequencing Instruments: Distribution by Maximum Read Length
  • Table 15.22 Single-cell Sequencing Instruments: Distribution by System Efficiency
  • Table 15.23 Single-cell Sequencing Instruments: Distribution by Sequencing Chemistry
  • Table 15.24 Single-cell Sequencing Instrument Providers: Distribution by Year of Establishment
  • Table 15.25 Single-cell Sequencing Instrument Providers: Distribution by Company Size
  • Table 15.26 Single-cell Sequencing Instrument Providers: Distribution by Location of Headquarters
  • Table 15.27 10x Genomics: Annual Revenues, 2017-Q2 2020 (USD Million)
  • Table 15.28 Fluidigm: Annual Revenues, 2015-Q2 2020 (USD Million)
  • Table 15.29 Illumina: Annual Revenues, 2013-Q2 2020 (USD Billion)
  • Table 15.30 Patent Analysis: Distribution by Patent Type
  • Table 15.31 Patent Analysis: Cumulative Distribution by Publication Year, 2015-2020
  • Table 15.32 Patent Analysis: Distribution by Geographical Location and Publication Year (Pre 2015- 2020)
  • Table 15.33 Patent Analysis: Distribution by Patent Type and Publication Year
  • Table 15.34 Patent Analysis: Distribution by Geographical Location
  • Table 15.35 Patent Analysis: Distribution by Jurisdiction
  • Table 15.36 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant (Pre 2015-2019)
  • Table 15.37 Leading Players: Distribution by Number of Patents
  • Table 15.38 Patent Analysis: Distribution of Patents by Geographical Region and Patent Type
  • Table 15.39 Single-cell Sequencing: Age of Patents
  • Table 15.40 Academic Grant Analysis: Cumulative Year-wise Trend, 2016-2020
  • Table 15.41 Academic Grant Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
  • Table 15.42 Academic Grant Analysis: Distribution by Activity Codes
  • Table 15.43 Academic Grant Analysis: Distribution by Support Period
  • Table 15.44 Academic Grant Analysis: Distribution by Funding Mechanism
  • Table 15.45 Academic Grant Analysis: Distribution by Type of Recipient Organization
  • Table 15.46 Popular Recipient Organizations: Distribution by Number of Grants
  • Table 15.47 Popular Recipient Organizations: Distribution by Amount Awarded (USD Million)
  • Table 15.48 Prominent Program Officers: Distribution by Number of Grants
  • Table 15.49 Recent Partnerships: Distribution by Year of Partnership
  • Table 15.50 Recent Partnerships: Distribution by Type of Agreement
  • Table 15.51 Recent Partnerships: Distribution by Focus Area of Partnership
  • Table 15.52 Recent Partnerships: Regional Distribution
  • Table 15.53 Recent Investments: Distribution by Year of Funding
  • Table 15.54 Recent Investments: Distribution by Type of Funding
  • Table 15.55 Recent Investments: Distribution by Amount Invested (USD Million)
  • Table 15.56 Most Active Players: Distribution by Amount Invested
  • Table 15.57 Most Active Investors: Distribution by Number of Funding Instances
  • Table 15.58 Recent Product Launches: Distribution by Year of Product Launch
  • Table 15.59 Recent Product Launches: Distribution by Type of Product
  • Table 15.60 Recent Product Launches: Distribution by Focus Area
  • Table 15.61 Most Active Players: Distribution by Number of Product Launches
  • Table 15.62 Overall Single-cell Sequencing Services and Technologies Market Opportunity, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.63 Single-cell Sequencing Services and Technologies Market Opportunity Across Key Market Segments, 2020 and 2030 (USD Million)
  • Table 15.64 Single-cell Sequencing Services and Technologies Market Opportunity: Distribution by Type of System, 2020 and 2030 (USD Million)
  • Table 15.65 Single-cell Sequencing Services and Technologies Market Opportunity: Distribution by End-User 2020 and 2030 (USD Million)
  • Table 15.66 Single-cell Sequencing Services and Technologies Market Opportunity: Distribution by Area of Application, 2020 and 2030 (USD Million)
  • Table 15.67 Single-cell Sequencing Services and Technologies Market Opportunity: Geographical Distribution, 2020 and 2030 (USD Million)
  • Table 15.68 Single-cell Sequencing Services and Technologies Market Opportunity in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.69 Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Service Providers, 2020-2030 (USD Million)
  • Table 15.70 Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Technology Providers, 2020-2030 (USD Million)
  • Table 15.71 Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Academic and Research Institutions, 2020-2030 (USD Million)
  • Table 15.72 Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
  • Table 15.73 Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Other End-Users, 2020-2030 (USD Million)
  • Table 15.74 Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Diagnostics, 2020-2030 (USD Million)
  • Table 15.75 Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Drug Discovery, 2020-2030 (USD Million)
  • Table 15.76 Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Precision Medicine, 2020-2030 (USD Million)
  • Table 15.77 Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Other Applications, 2020-2030 (USD Million)
  • Table 15.78 Single-cell Sequencing Services and Technologies Market Opportunity in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.79 Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Service Providers, 2020-2030 (USD Million)
  • Table 15.80 Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Technology Providers, 2020-2030 (USD Million)
  • Table 15.81 Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Academic and Research Institutions, 2020-2030 (USD Million)
  • Table 15.82 Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
  • Table 15.83 Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Other End-Users, 2020-2030 (USD Million)
  • Table 15.84 Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Diagnostics, 2020-2030 (USD Million)
  • Table 15.85 Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Drug Discovery, 2020-2030 (USD Million)
  • Table 15.86 Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Precision Medicine, 2020-2030 (USD Million)
  • Table 15.87 Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Other Applications, 2020-2030 (USD Million)
  • Table 15.88 Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.89 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Service Providers, 2020-2030 (USD Million)
  • Table 15.90 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Technology Providers, 2020-2030 (USD Million)
  • Table 15.91 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Academic and Research Institutions, 2020-2030 (USD Million)
  • Table 15.92 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
  • Table 15.93 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Other End-Users, 2020-2030 (USD Million)
  • Table 15.94 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Diagnostics, 2020-2030 (USD Million)
  • Table 15.95 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Drug Discovery, 2020-2030 (USD Million)
  • Table 15.96 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Precision Medicine, 2020-2030 (USD Million)
  • Table 15.97 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Other Applications, 2020-2030 (USD Million)
  • Table 15.98 Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 15.99 Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Service Providers, 2020-2030 (USD Million)
  • Table 15.100 Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Technology Providers, 2020-2030 (USD Million)
  • Table 15.101 Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Academic and Research Institutions, 2020-2030 (USD Million)
  • Table 15.102 Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
  • Table 15.103 Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Other End-Users, 2020-2030 (USD Million)
  • Table 15.104 Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Diagnostics, 2020-2030 (USD Million)
  • Table 15.105 Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Drug Discovery, 2020-2030 (USD Million)
  • Table 15.106 Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Precision Medicine, 2020-2030 (USD Million)
  • Table 15.107 Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Other Applications, 2020-2030 (USD Million)

List Of Company

The following companies and organizations have been included in the report:

  • 1. 10x Genomics
  • 2. 1CellBio
  • 3. Active Motif
  • 4. Admera Health
  • 5. Aelian Biotechnology
  • 6. Agency for Science Technology and Research
  • 7. Agilent Technologies
  • 8. Albert Einstein College of Medicine
  • 9. Annoroad Gene Technology
  • 10. Australian Genome Research Facility
  • 11. Becton Dickinson
  • 12. BGI Genomics
  • 13. Bigelow Single Cell Genomics Centre
  • 14. Bioinformatics and Expression Analysis Core Facility (Karolinska Institutet)
  • 15. BioLegend
  • 16. Immudex
  • 17. Biomedical Research Core Facilities (University of Michigan Medical School)
  • 18. Biopolymers Facility (Harvard Medical School)
  • 19. Bio-Rad Laboratories
  • 20. Biotech Research and Innovation Centre (University of Copenhagen)
  • 21. Biotechnology Center (University of Wisconsin-Madison)
  • 22. Broad Institute
  • 23. Bucher Biotec
  • 24. California Institute of Technology
  • 25. Cancer Genomics Center (University of Texas)
  • 26. Cancer Research UK Cambridge Institute (University of Cambridge)
  • 27. CARTANA
  • 28. CD Genomics
  • 29. Cedars-Sinai Genomics Core
  • 30. Cell Biologics
  • 31. Cell Microsystems
  • 32. Cellarity
  • 33. CellChorus
  • 34. Celldom
  • 35. CellTool
  • 36. Cellular Research
  • 37. Celsee
  • 38. Celsius Therapeutics
  • 39. Center for Gastrointestinal Biology and Disease (University of North Carolina School of Medicine)
  • 40. Center for Genetic Medicine (Northwestern University)
  • 41. Center for Translational Genomics (Lund University)
  • 42. Centre for Genome-Enabled Biology and Medicine (University of Aberdeen)
  • 43. Centre for Health Genomics and Informatics (University of Calgary)
  • 44. Centro Nacional de Análisis Genómico
  • 45. Clearbridge BioMedics
  • 46. Cleveland Clinic
  • 47. Cold Spring Harbor Laboratory
  • 48. Columbia Genome Center (Columbia University)
  • 49. Core Facility Genomics (Amsterdam UMC)
  • 50. Core Immunology Lab (University of California)
  • 51. Covance
  • 52. Cytena
  • 53. Cytomos
  • 54. Cytosurge
  • 55. DNA Core Facility (University of Missouri)
  • 56. DNA Technologies Core (University of California Davis)
  • 57. Dolomite Bio
  • 58. Droplet Genomics
  • 59. Duke Molecular Physiology Institute
  • 60. Earlham Institute
  • 61. Eldan
  • 62. Enigma Life Sciences
  • 63. Epigenomics and DNA Sequencing Core Facility (NIH)
  • 64. Epinomics
  • 65. Exosomeplus
  • 66. FlowJo
  • 67. Fluidigm
  • 68. Fulgent Genetics
  • 69. Functional Genomics Center Zurich (University of Zurich)
  • 70. GenapSys
  • 71. Genentech
  • 72. Genetic Resources Core Facility (Johns Hopkins University)
  • 73. GENEWIZ
  • 74. Genome Quebec
  • 75. Genome Sequencing Service Center (Stanford University)
  • 76. Genome Technology Access Center (Washington University)
  • 77. GenomeScan
  • 78. Genomics Core Facility (European Molecular Biology Laboratory)
  • 79. Genomics Core Facility (Lewis-Sigler Institute for Integrative Genomics)
  • 80. Genomics Facility (University of Chicago)
  • 81. Genuity Science
  • 82. Gladstone Genomics Core
  • 83. Hangzhou Chengyuan Genomics
  • 84. Harvard College
  • 85. Harvard University
  • 86. Huntsman Cancer Institute (University of Utah)
  • 87. Illumina
  • 88. Imperial BRC Genomics Facility (Imperial College London)
  • 89. Imperial Life Sciences
  • 90. InCellDx
  • 91. Indiana University School of Medicine (Indiana University)
  • 92. Institute for Genome Sciences (University of Maryland School of Medicine)
  • 93. Institute for Molecular Bioscience (University of Queensland)
  • 94. Intermountain Healthcare
  • 95. Iowa Institute of Human Genetics (University of Iowa)
  • 96. IsoPlexis
  • 97. Johnson & Johnson
  • 98. Katholieke Universiteit Leuven
  • 99. Kinghorn Medical Center (Garvan-Weizmann Medical Center)
  • 100. LC Sciences
  • 101. LMU University Hospital
  • 102. LumaCyte
  • 103. Massachusetts General Hospital
  • 104. Massachusetts Institute of Technology
  • 105. University of Texas MD Anderson Cancer Center
  • 106. MedGenome
  • 107. MGI
  • 108. MilliporeSigma
  • 109. Minos Biosciences
  • 110. Mission Bio
  • 111. Monash Health Translation Product Medical Genomics Facility
  • 112. NanoString Technologies
  • 113. Nashville Biosciences
  • 114. Natera
  • 115. NeuroInDx
  • 116. nference
  • 117. Novogene
  • 118. Nucleome Informatics
  • 119. NXTGNT (Ghent University)
  • 120. OICR Genomics and Bioinformatics
  • 121. Onconova Therapeutics
  • 122. Ottawa Hospital Research Institute
  • 123. Oxford Genetics (University of Edinburgh)
  • 124. Oxford Genomics Centre (University of Oxford)
  • 125. Oxford Nanopore Technologies
  • 126. Pacific Biosciences
  • 127. Partek
  • 128. Peak Analysis and Automation
  • 129. Perelman School of Medicine (University of Pennsylvania)
  • 130. PerkinElmer
  • 131. Petri
  • 132. Pittsburgh Liver Research Centre (University of Pittsburgh)
  • 133. Princess Margaret Genomics Centre
  • 134. Proteona
  • 135. Psomagen
  • 136. QB3 Genomics (University of California, Berkeley)
  • 137. QIAGEN
  • 138. Quick Biology
  • 139. Ramaciotti Centre for Genomics
  • 140. ReadCoor
  • 141. Rockefeller University
  • 142. RootPath
  • 143. S2 Genomics
  • 144. Saban Research Institute
  • 145. Salk Institute of Biological Sciences
  • 146. Sanford Burnham Prebys Medical Discovery Institute
  • 147. Scailyte
  • 148. SciLifeLab
  • 149. Scipio Bioscience
  • 150. Semel Institute for Neuroscience and Behavior (University of California)
  • 151. SeqLL
  • 152. SeqMatic
  • 153. Sequencing Core Facility (Max Planck Institute for Molecular Genetics)
  • 154. seqWell
  • 155. Singleron Biotechnologies
  • 156. Single Cell Analysis Facility (NCI Frederick Accessioning)
  • 157. Single Cell Discoveries
  • 158. Single Cell Genomics Core (Baylor College of Medicine)
  • 159. Single Cell Genomics Core (Brigham and Women's Hospital)
  • 160. Single Cell Sequencing Core - Department of Medicine (Boston University)
  • 161. Singlera Genomics
  • 162. SingulOmics
  • 163. Spanish National Center for Cardiovascular Research
  • 164. Spatial Transcriptomics
  • 165. Sphere Fluidics
  • 166. Split Bioscience
  • 167. St. Jude Children's Research Hospital
  • 168. Stanford University
  • 169. Sylvester Comprehensive Cancer Center (University of Miami)
  • 170. Takara Bio
  • 171. Technology Center for Genetics and Bioinformatics (University of California)
  • 172. Turku Bioscience (University of Turku)
  • 173. University of Auckland
  • 174. University of Buffalo Genomics and Bioinformatics Core
  • 175. University of California
  • 176. University of Helsinki
  • 177. University of Kansas Medical Center
  • 178. University of Oxford
  • 179. University of Texas
  • 180. UT Southwestern Medical Center (University of Texas)
  • 181. Vanderbilt Technologies for Advanced Genomics
  • 182. VIB Nucleomics Core (VIB)
  • 183. VyCAP
  • 184. WaferGen Bio-systems
  • 185. Wellcome Sanger Institute
  • 186. Wexner Medical Center (Ohio State University)
  • 187. Wistar Institute
  • 188. X Gen
  • 189. Yale Center for Genome Analysis (Yale School of Medicine)
  • 190. Yerkes National Primate Research Center (Emory University)
  • 191. Zephyrus Biosciences
  • 192. Zomedica Pharmaceuticals